Skip to search formSkip to main contentSkip to account menu

Neupogen

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
RATIONALE & OBJECTIVES: Biosimilar filgrastim may offer significant cost advantages over originator filgrastim and pegfilgrastim… 
2016
2016
Solid-organ transplant graft-versus-host disease (SOT-GVHD) is a rare complication of organ transplant that is associated with… 
2015
2015
Methods: A PDMDD model was developed by combining elements from a cell-level model of target interaction [1] with a traditional… 
2015
2015
Background : There are little differences between biosimilars and reference products. Therefore, these products must be compared… 
2014
2014
Aim: To demonstrate biosimilarity as evidenced by the pharmacokinetic (PK), pharmacodynamics (PD), efficacy and safety… 
2008
2008
Objectives: Offspring of women with gestational diabetes mellitus (GDM) are at increased risk for obesity and diabetes mellitus… 
Review
2006
Review
2006
The authors present their own observation of a patient suffering from drug-induced agranulocytosis, cured with filgastrim… 
1998
1998
A home intravenous drug therapy provider and an insurance company operated by the American Consulting Engineers Council have… 
1996
1996
High‐dose melphalan (HDM) is now a standard treatment for multiple myeloma (MM). Stem cell transplants are fast evolving as an… 
1996
1996
Neupogen, or recombinant granulocyte colony-stimulating factor, is a neutrophil growth factor developed by Amgen. Neupogen has…